 |
市場調査レポート
商品コード
1440023
がんバイオマーカー - 世界の市場考察、競合情勢、市場予測（2030年）Cancer Biomarkers - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。 詳細はお問い合わせください。
| がんバイオマーカー - 世界の市場考察、競合情勢、市場予測（2030年） |
|
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
|
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
- 全表示
- 概要
- 図表
- 目次
世界のがんバイオマーカーの市場規模は、2024年～2030年の予測期間にCAGRで13.73%の成長が見込まれます。市場は、世界中でのさまざまなタイプのがんの有病率の増加や、喫煙や高脂肪食といったがん発症の危険因子を持つ人々の増加、がんバイオマーカー分野における研究開発活動が活発化し、新製品の上市や規制当局の承認が増加していることなどから、楽観的な市場成長を示しており、予測期間（2024年～2030年）における市場の収益成長がさらに予測されています。
がんバイオマーカーの市場力学
がんバイオマーカー市場の主な成長要因の1つが、世界の各種がんの有病率の増加です。世界保健機関（WHO）（2022）のデータによると、2020年に世界で乳がん226万件、肺がん221万件、大腸がん193万件、前立腺がん141万件、胃がん109万件が報告されました。
また、GLOBOCAN（2022）が提供したデータによると、2020年に世界中で約1,929万2,789件の新たながん症例が報告されています。上記の資料によれば、2040年までに、肝臓がん140万人、肺がん363万人、腎臓がん66万6,000人を含む、約2,888万7,942人のがん患者が新たに発生すると推定されています。
世界中でがんに罹患する患者が多いことから、診断や予後予測、研究開発活動が大幅に増加すると予測され、このことが予測期間（2024年～2030年）にがんバイオマーカー市場の需要に拍車をかける可能性があります。
しかし、サンプルの収集や保管に関する技術的問題や、研究開発活動で発生する高いコスト、限られたインフラ施設などが、がんバイオマーカー市場の成長抑制要因として作用する可能性があります。
がんバイオマーカー市場は、COVID-19パンデミック中にマイナスの影響を受けました。パンデミックの初期段階では、医療施設の大半がCOVID-19の状況に対処していたことから、厳格なロックダウン規則の賦課、資金不足、サンプル採取の減少により、すべてのがんバイオマーカー検査、診断、研究活動の収益が落ち込みました。また、パンデミック中、COVID-19患者は診断と治療の面でより優先され、その結果、緊急事態や緊急の治療が必要な場合を除き、がんの診断と治療は減少しました。しかし、ロックダウン規制の緩和、リソースとサプライチェーンの好転、大衆へのワクチン投与によってがんバイオマーカーの需要は増加しており、2022年～2028年の予測期間に成長する見込みです。
がんバイオマーカー市場のセグメント分析
がんバイオマーカー市場のがん種セグメントでは、2023年までに乳がんセグメントが大きな収益シェアを占めると予測されています。これは、世界中での乳がんの有病率の増加や、タイムリーな診断と治療を強化する政府の取り組みの増加、予測期間の乳がんバイオマーカーセグメントにおける研究開発活動の活発化によるものと考えられます。
世界保健機関（WHO）の2022年のデータによると、2020年に世界で230万人の女性が乳がんと診断されました。さらに、同じ資料によると、2020年末までに、過去5年間に乳がんと診断された生存中の女性は780万人であり、世界でもっとも罹患率の高いがんとなっています。
さらに、乳がん診断市場のもう1つの主な成長要因が、特定の国家政府による、早期のスクリーニングと診断に関する認識を高める取り組みの増加です。例えば、2022年3月、WHOは世界の乳がん死亡率を年間2.5%削減するGlobal Breast Cancer Initiative（GBCI）を立ち上げ、これにより、2030年までに乳がんによる死亡の25%を予防し、2040年までに70歳未満の女性の乳がんによる死亡の40%を予防するとしています。
2019年5月、QiagenはNovartisが開発および販売する新規承認治療薬であるPIQRAY（アルペリシブ）による治療の対象となる乳がん患者の同定を支援するコンパニオン診断薬としての米国規制当局（FDA）の承認を取得した後、Therascreen® PIK3CA RGQ PCR Kit（therascreen PIK3CA Kit）を即座に発売することを発表しました。
当レポートでは、世界のがんバイオマーカー市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。
目次
第1章 がんバイオマーカー市場レポートのイントロダクション
第2章 がんバイオマーカー市場のエグゼクティブサマリー
- 調査範囲
- 市場の概要
- 競合の評価
第3章 規制分析
第4章 がんバイオマーカー市場の主な要因の分析
- がんバイオマーカー市場の促進要因
- がんバイオマーカー市場の抑制要因と課題
- がんバイオマーカー市場の機会
第5章 がんバイオマーカー市場のポーターのファイブフォース分析
第6章 がんバイオマーカー市場に対するCOVID-19の影響の分析
第7章 がんバイオマーカー市場のレイアウト
- タイプ別
- タンパク質
- 遺伝子
- その他
- がん種別
- 乳
- 肺
- 大腸
- 前立腺
- 技術別
- オミックス
- イメージング
- イムノアッセイ
- 用途別
- 診断
- ドラッグデリバリー
- 予測
- 地域
- 北米
- 欧州
- アジア太平洋
- その他の地域
第8章 がんバイオマーカー市場の企業と製品のプロファイル
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific, Inc.
- QIAGEN N.V.
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- Abbott Laboratories
- bioMerieux SA
- BD
- Merck Millipore
- Agilent Technologies
- Myriad Genetics
- Sysmex Corporation
- Hologic, Inc.
- Quest Diagnostics
- Centogene N.V.
- PerkinElmer, Inc.
- Siemens Healthineers
- Exact Sciences
- R&D Systems, Inc.
- BioVision, Inc.
第9章 KOLの見解
第10章 プロジェクトのアプローチ
第11章 DelveInsightについて
第12章 免責事項、お問い合わせ
List of Tables
- Table 1: Competitive Analysis
- Table 2: COVID-19 Impact Analysis on Cancer Biomarkers Market
- Table 3: Cancer Biomarkers Market Analysis in Global (2021-2030)
- Table 4: Cancer Biomarkers Market Analysis in Global by Type (2021-2030)
- Table 5: Cancer Biomarkers Market Analysis in Global by Cancer Type (2021-2030)
- Table 6: Cancer Biomarkers Market Analysis in Global by Technology (2021-2030)
- Table 7: Cancer Biomarkers Market Analysis in Global by Application(2021-2030)
- Table 8: Cancer Biomarkers Market Analysis in Global by Geography (2021-2030)
- Table 9: Cancer Biomarkers Market Analysis in North America (2021-2030)
- Table 10: Cancer Biomarkers Market Analysis in North America by Country (2021-2030)
- Table 11: Cancer Biomarkers Market Analysis in the US (2021-2030)
- Table 12: Cancer Biomarkers Market Analysis in Canada (2021-2030)
- Table 13: Cancer Biomarkers Market Analysis in Mexico (2021-2030)
- Table 14: Cancer Biomarkers Market Analysis in Europe (2021-2030)
- Table 15: Cancer Biomarkers Market Analysis in Europe by Country (2021-2030)
- Table 16: Cancer Biomarkers Market Analysis in France (2021-2030)
- Table 17: Cancer Biomarkers Market Analysis in Germany (2021-2030)
- Table 18: Cancer Biomarkers Market Analysis in the UK (2021-2030)
- Table 19: Cancer Biomarkers Market Analysis in Italy (2021-2030)
- Table 20: Cancer Biomarkers Market Analysis in Spain (2021-2030)
- Table 21: Cancer Biomarkers Market Analysis in the Rest of Europe (2021-2030)
- Table 22: Cancer Biomarkers Market Analysis in Asia-Pacific (2021-2030)
- Table 23: Cancer Biomarkers Market Analysis in Asia-Pacific by Country (2021-2030)
- Table 24: Cancer Biomarkers Market Analysis in China (2021-2030)
- Table 25: Cancer Biomarkers Market Analysis in Japan (2021-2030)
- Table 26: Cancer Biomarkers Market Analysis in India (2021-2030)
- Table 27: Cancer Biomarkers Market Analysis in Australia (2021-2030)
- Table 28: Cancer Biomarkers Market Analysis in South Korea (2021-2030)
- Table 29: Cancer Biomarkers Market Analysis in Rest of Asia-Pacific (2021-2030)
- Table 30: Cancer Biomarkers Market Analysis in the Rest of the World (2021-2030)
- Table 31: Cancer Biomarkers Market Analysis in the Rest of the World by Region (2021-2030)
- Table 32: Cancer Biomarkers Market Analysis in the Middle East (2021-2030)
- Table 33: Cancer Biomarkers Market Analysis in Africa (2021-2030)
- Table 34: Cancer Biomarkers Market Analysis in South America (2021-2030)
List of Figures
- Figure 1: Competitive Analysis
- Figure 2: COVID-19 Impact Analysis on Cancer Biomarkers Market
- Figure 3: Cancer Biomarkers Market Analysis in Global (2021-2030)
- Figure 4: Cancer Biomarkers Market Analysis in Global by Type (2021-2030)
- Figure 5: Cancer Biomarkers Market Analysis in Global by Cancer Type (2021-2030)
- Figure 6: Cancer Biomarkers Market Analysis in Global by Technology (2021-2030)
- Figure 7: Cancer Biomarkers Market Analysis in Global by Application (2021-2030)
- Figure 8: Cancer Biomarkers Market Analysis in Global by Geography (2021-2030)
- Figure 9: Cancer Biomarkers Market Analysis in North America (2021-2030)
- Figure 10: Cancer Biomarkers Market Analysis in North America by Country (2021-2030)
- Figure 11: Cancer Biomarkers Market Analysis in the US (2021-2030)
- Figure 12: Cancer Biomarkers Market Analysis in Canada (2021-2030)
- Figure 13: Cancer Biomarkers Market Analysis in Mexico (2021-2030)
- Figure 14: Cancer Biomarkers Market Analysis in Europe (2021-2030)
- Figure 15: Cancer Biomarkers Market Analysis in Europe by Country (2021-2030)
- Figure 16: Cancer Biomarkers Market Analysis in France (2021-2030)
- Figure 17: Cancer Biomarkers Market Analysis in Germany (2021-2030)
- Figure 18: Cancer Biomarkers Market Analysis in the UK (2021-2030)
- Figure 19: Cancer Biomarkers Market Analysis in Italy (2021-2030)
- Figure 20: Cancer Biomarkers Market Analysis in Spain (2021-2030)
- Figure 21: Cancer Biomarkers Market Analysis in the Rest of Europe (2021-2030)
- Figure 22: Cancer Biomarkers Market Analysis in Asia-Pacific (2021-2030)
- Figure 23: Cancer Biomarkers Market Analysis in Asia-Pacific by Country (2021-2030)
- Figure 24: Cancer Biomarkers Market Analysis in China (2021-2030)
- Figure 25: Cancer Biomarkers Market Analysis in Japan (2021-2030)
- Figure 26: Cancer Biomarkers Market Analysis in India (2021-2030)
- Figure 27: Cancer Biomarkers Market Analysis in Australia (2021-2030)
- Figure 28: Cancer Biomarkers Market Analysis in South Korea (2021-2030)
- Figure 29: Cancer Biomarkers Market Analysis in Rest of Asia-Pacific (2021-2030)
- Figure 30: Cancer Biomarkers Market Analysis in the Rest of the World (2021-2030)
- Figure 31: Cancer Biomarkers Market Analysis in the Rest of the World by Region (2021-2030)
- Figure 32: Cancer Biomarkers Market Analysis in the Middle East (2021-2030)
- Figure 33: Cancer Biomarkers Market Analysis in Africa (2021-2030)
- Figure 34: Cancer Biomarkers Market Analysis in South America (2021-2030)
- Figure 35: Market Drivers
- Figure 36: Market Barriers
- Figure 37: Market Opportunities
- Figure 38: PORTER's Five Force Analysis
Cancer biomarkers market by type (protein, genetic, and others), by cancer type (breast, lung, colorectal, prostate, and others), by technology (omics, imaging, immunoassay, and others), by application (diagnostics, drug delivery, prognostics, and others), and by geography is expected to advance at a respectable CAGR forecast till 2030 owing to the rising prevalence of cancer worldwide, increase in the risk factors for cancer development, the increasing research & development activities leading to new product launches and approvals in the cancer biomarkers arena across the globe
The global Cancer Biomarkers Market is estimated to grow at a CAGR of 13.73% during the forecast period from 2024 to 2030. The Cancer Biomarkers market is observing an optimistic market growth owing to an increase in the prevalence of various types of cancers globally, the growing population with risk factors for cancer development such as smoking, and high-fat diet, among others, and the increasing research & development activities in the cancer biomarkers arena leading to new product launches and increasing regulatory approvals are further expected to result in appreciable revenue growth of the Cancer Biomarkers market during the forecast period (2024-2030).
Cancer Biomarkers Market Dynamics:
One of the main factors for the growth of the Cancer Biomarkers market increase in the prevalence of various types of cancers globally. As per the data cited by the World Health Organization 2022, worldwide around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020.
In addition, according to the data provided by GLOBOCAN 2022, worldwide around 19,292,789 new cancer cases were reported in 2020. As per the above-mentioned source, it has been estimated that worldwide there will be around 28,887,942 new cancer cases including 1.40 million new cases of liver, 3.63 million cases of lung, and 666 thousand new cases of kidney cancer, by 2040.
Owing to the presence of a large patient pool suffering from cancers worldwide, the diagnostic and prognostic procedures along with the research and development activities are expected to rise substantially, which would spur the market demand for cancer biomarkers during the forecast period (2024-2030).
However, certain technical issues related to sample collection and storage, high costs incurred in research and development activities, limited infrastructural facilities, and others may act as restraints for the cancer biomarkers market growth.
The Cancer Biomarkers market was negatively impacted during the COVID-19 pandemic. During the initial stage of the pandemic, the sales of all the cancer biomarker tests, diagnoses, and research activities suffered a downfall owing to the imposition of strict lockdown rules, lack of funding, and less sample collection as the majority of the healthcare facilities were involved in tackling the situation of COVID-19. Also, during the pandemic, COVID-19 patients were given more preference in terms of diagnosis and treatment, and this leads to a decreased number of diagnoses and treatments for cancer unless and until the cases involved emergencies or required immediate treatments. However, with the ease of lockdown restrictions, the upturn of resources, and supply chain, and the administration of the vaccine to the public, the demand for cancer biomarkers increased and is expected to grow during the forecast period from 2022 - 2028.
Cancer Biomarkers Market Segment Analysis:
Cancer Biomarkers market by type (protein, genetic, and others), cancer type (breast, lung, colorectal, prostate, and others), technology (Omics, imaging, immunoassay, and others), application (diagnostics, drug delivery, prognostics, and others), and geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the cancer type segment of the cancer biomarkers market, the breast cancer segment is expected to have a significant revenue share in the year 2023. This can be attributed to the growing prevalence of breast cancer around the world, the growing number of government initiatives to reinforce timely diagnosis and treatment, along with the rising research and developmental activities in the breast cancer biomarkers segment during the forecast period.
As per the World Health Organization (WHO) 2022 data, in 2020 breast cancer was diagnosed in 2.3 million women globally. Further, as per the same source by the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the last 5 years, making it the world's most prevalent cancer.
Moreover, another key factor that is responsible for the growth of the breast cancer diagnostics market is the rising number of initiatives taken by specific national governments to increase awareness about early screening and diagnosis. For instance, in March 2022, WHO launched a Global Breast Cancer Initiative (GBCI) to reduce global breast cancer mortality by 2.5% per year, which would prevent 25% of breast cancer deaths by 2030 and 40% by 2040 among women under 70 years.
In May 2019, Qiagen, announced the immediate launch of its Therascreen® PIK3CA RGQ PCR Kit (therascreen PIK3CA Kit) after it received the U.S. regulatory (FDA) approval as a companion diagnostic to aid in identifying breast cancer patients eligible for treatment with PIQRAY (alpelisib), a newly approved therapy developed and marketed by Novartis.
Therefore, owing to the aforementioned factors, it is expected that the demand for cancer biomarkers in the breast cancer segment will increase, thereby propelling the overall market for Cancer Biomarkers during the forecast period from 2022-2028.
North America is expected to dominate the overall Cancer Biomarkers Market:
Among all the regions, North America is expected to dominate the global Cancer Biomarkers market in the year 2023 and is expected to do the same during the forecast period from 2024-2030. This domination is due to the rising prevalence of various types of cancers, along with the rising product developmental activities in North America, among others.
As per the figures mentioned by the American Cancer Society 2022, it was estimated that 1.9 million new cancer cases have been diagnosed in the United States in the year 2023. Also, according to the data provided by the Centers for Disease Control and Prevention (CDC) 2022, around 1,752,735 new cases of cancer were reported in the US in 2019. These staggering numbers of cancer prevalence are further expected to bolster the demand for more cancer biomarker identification as early diagnosis is the only way to fight cancer.
In December 2022, The US Food and Drug Administration (FDA) granted premarket approval for Thermo Fisher Scientific's Oncomine Dx Target Test as a companion diagnostic (CDx) to help identify non-small cell lung cancer (NSCLC) patients whose tumors carry epidermal growth factor receptor (EGFR) Exon20-insertion mutations. Thermo Fisher's Oncomine Dx Target Test simultaneously evaluates 23 genes associated with NSCLC.
Therefore, the interplay of various factors such as the presence of a large patient population, as well as product development activities such as gaining regulatory approvals by key market players in the region is expected to boost the North America cancer biomarkers market during the forecast period.
Cancer Biomarkers Market Key Players:
Some of the key market players operating in the Cancer Biomarkers Market include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMerieux SA, BD, Merck Millipore, Agilent Technologies, Myriad Genetics, Sysmex Corporation, Hologic, Inc., Quest Diagnostics, Centogene N.V., PerkinElmer, Inc., Siemens Healthineers, Exact Sciences, R&D Systems, Inc., BioVision, Inc., and others.
Recent Developmental Activities in the Cancer Biomarkers Market:
In February 2022, OncoDNA, a genomic and theranostic company announced the launch of OncoDeep kit, integrating both reagents and quality control standards for the sequencing of over 600 cancer biomarkers, which provide powerful data analysis and support oncologists in the most effective and personalized treatments for cancer patients.
In April 2022, Roche announced the launch of Elecsys Anti-p53 immunoassay for the in vitro quantitative determination of anti-p53 antibodies. This immunoassay is used to aid physicians in the diagnosis of throat cancer, bowel cancer, and breast cancer in patients, in conjunction with other diagnostic tests.
In July 2020, Vector Laboratories launched the Glysite Scout Glycan Screening Kits enabling researchers to understand the relevance of glycomics in the collected samples for association with post-translational protein modifications and biomarkers of disease. The Vector Laboratories curated lectin selection allowed researchers to detect the presence or absence of all major surface glycan motifs in a sample, offering insight into disease progression, and determining the effectiveness of treatment or stimulus, thus allowing better characterization of cell and tissue types.
Key Takeaways from the Cancer Biomarkers Market Report Study
- Market size analysis for current Cancer Biomarkers Market size (2023), and market forecast for 5 years (2024-2030)
- The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Cancer Biomarkers market.
- Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
- Key companies dominating the global Cancer Biomarkers market.
- Various opportunities available for the other competitor in the Cancer Biomarkers Market space.
- What are the top-performing segments in 2023? How these segments will perform in 2030.
- Which are the top-performing regions and countries in the current Cancer Biomarkers Market scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for Cancer Biomarkers market growth in the coming future?
Target Audience who can be benefited from this Cancer Biomarkers Market Report Study
- Cancer Biomarkers products providers
- Research and development organizations
- Cancer Biomarkers-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and Traders dealing in Cancer Biomarkers
- Various end users who want to know more about the Cancer Biomarkers market and the latest innovations in the Cancer Biomarkers market.
Frequently Asked Questions for the Cancer Biomarkers Market:
1. What are cancer biomarkers?
Cancer biomarkers are biological molecules that help in determining the presence of cancer in a patient. They are either produced by the cancer cells or by non-cancer cells in response to cancer onset and progression. They can be identified from serum and can be used for personalized daily care in screening, diagnosis, establishing prognosis, monitoring treatment, and detecting relapse.
2. What is the global market for Cancer Biomarkers?
The global Cancer Biomarkers Market is estimated to grow at a CAGR of 13.73% during the forecast period from 2024 to 2030.
3. What are the drivers for the global Cancer Biomarkers market?
The Cancer Biomarkers market is witnessing positive growth due to an increase in the prevalence of various types of cancers globally, the rising population with risk factors for cancer development such as smoking, and obesity, among others, and the increasing research and development activities in the cancer biomarkers arena leading to more product launches and regulatory approvals are further expected to result in appreciable revenue growth of the Cancer Biomarkers market during the forecast period (2024-2030).
4. Who are the key players operating in the global Cancer Biomarkers market?
Some of the key market players operating in the Cancer Biomarkers market include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMerieux SA, BD, Merck Millipore, Agilent Technologies, Myriad Genetics, Sysmex Corporation, Hologic, Inc., Quest Diagnostics, Centogene N.V., PerkinElmer, Inc., Siemens Healthineers, Exact Sciences, R&D Systems, Inc., BioVision, Inc., and others.
5. Which region has the highest share in the Cancer Biomarkers market?
Among all the regions, North America is estimated to amass a significant revenue share in the global Cancer Biomarkers market. This domination is due to the rising prevalence of various types of cancers, the growing number of government initiatives to reinforce timely diagnosis and treatment, and the rising product developmental activities in North America, among others, during the forecast period.
Table of Contents
1. Cancer Biomarkers Market Report Introduction
2. Cancer Biomarkers Market Executive Summary
- 2.1. Scope of the Study
- 2.2. Market at Glance
- 2.3. Competitive Assessment
3. Regulatory Analysis
4. Cancer Biomarkers Market Key Factors Analysis
- 4.1. Cancer Biomarkers Market Drivers
- 4.1.1. The rise in the prevalence of various types of cancers worldwide.
- 4.1.2. Increase in the number of population with associated risk factors for cancer development
- 4.1.3. The increasing research and development activities leading to product launches and approvals
- 4.2. Cancer Biomarkers Market Restraints and Challenges
- 4.2.1. Technical issues related to sample collection and storage
- 4.2.2. High costs incurred in research and development activities and limited infrastructural facilities
- 4.3. Cancer Biomarkers Market Opportunities
- 4.3.1. Improving test safety and accuracy
- 4.3.2. The untapped potential of emerging markets with the development of innovative and latest test procedures for diagnosis and drug delivery
5. Cancer Biomarkers Market Porter's Five Forces Analysis
- 5.1. Bargaining Power of Suppliers
- 5.2. Bargaining Power of Consumers
- 5.3. Threat of New Entrants
- 5.4. Threat of Substitutes
- 5.5. Competitive Rivalry
6. COVID-19 Impact Analysis on Cancer Biomarkers Market
7. Cancer Biomarkers Market Layout
- 7.1. By Type
- 7.1.1. Protein
- 7.1.2. Genetic
- 7.1.3. Others
- 7.2. By Cancer Type
- 7.2.1. Breast
- 7.2.2. Lung
- 7.2.3. Colorectal
- 7.2.4. Prostate
- 7.2.5. Others
- 7.3. By Technology
- 7.3.1. Omics
- 7.3.2. Imaging
- 7.3.3. Immunoassay
- 7.3.4. Others
- 7.4. By Application
- 7.4.1. Diagnostics
- 7.4.2. Drug Delivery
- 7.4.3. Prognostics
- 7.4.4. Others
- 7.5. By Geography
- 7.5.1. North America
- 7.5.1.1. United States Cancer Biomarkers Market in USD million (2021-2030)
- 7.5.1.2. Canada Cancer Biomarkers Market in USD million (2021-2030)
- 7.5.1.3. Mexico Cancer Biomarkers Market in USD million (2021-2030)
- 7.5.2. Europe
- 7.5.2.1. France Cancer Biomarkers Market in USD million (2021-2030)
- 7.5.2.2. Germany Cancer Biomarkers Market in USD million (2021-2030)
- 7.5.2.3. United Kingdom Cancer Biomarkers Market in USD million (2021-2030)
- 7.5.2.4. Italy Cancer Biomarkers Market in USD million (2021-2030)
- 7.5.2.5. Spain Cancer Biomarkers Market in USD million (2021-2030)
- 7.5.2.6. Rest of Europe Cancer Biomarkers Market in USD million (2021-2030)
- 7.5.3. Asia-Pacific
- 7.5.3.1. China Cancer Biomarkers Market in USD million (2021-2030)
- 7.5.3.2. Japan Cancer Biomarkers Market in USD million (2021-2030)
- 7.5.3.3. India Cancer Biomarkers Market in USD million (2021-2030)
- 7.5.3.4. Australia Cancer Biomarkers Market in USD million (2021-2030)
- 7.5.3.5. South Korea Cancer Biomarkers Market in USD million (2021-2030)
- 7.5.3.6. Rest of Asia Pacific Cancer Biomarkers Market in USD million (2021-2030)
- 7.5.4. Rest of the World (RoW)
- 7.5.4.1. Middle East Cancer Biomarkers Market in USD million (2021-2030)
- 7.5.4.2. Africa Cancer Biomarkers Market in USD million (2021-2030)
- 7.5.4.3. South America Cancer Biomarkers Market in USD million (2021-2030)
- 7.5.1. North America
8. Cancer Biomarkers Market Company and Product Profiles
- 8.1. F. Hoffmann-La Roche Ltd.
- 8.1.1. Company Overview
- 8.1.2. Company Snapshot
- 8.1.3. Financial Overview
- 8.1.4. Product Listing
- 8.1.5. Entropy
- 8.2. Thermo Fisher Scientific, Inc.
- 8.2.1. Company Overview
- 8.2.2. Company Snapshot
- 8.2.3. Financial Overview
- 8.2.4. Product Listing
- 8.2.5. Entropy
- 8.3. QIAGEN N.V.
- 8.3.1. Company Overview
- 8.3.2. Company Snapshot
- 8.3.3. Financial Overview
- 8.3.4. Product Listing
- 8.3.5. Entropy
- 8.4. Illumina, Inc.
- 8.4.1. Company Overview
- 8.4.2. Company Snapshot
- 8.4.3. Financial Overview
- 8.4.4. Product Listing
- 8.4.5. Entropy
- 8.5. Bio-Rad Laboratories, Inc.
- 8.5.1. Company Overview
- 8.5.2. Company Snapshot
- 8.5.3. Financial Overview
- 8.5.4. Product Listing
- 8.5.5. Entropy
- 8.6. Abbott Laboratories
- 8.6.1. Company Overview
- 8.6.2. Company Snapshot
- 8.6.3. Financial Overview
- 8.6.4. Product Listing
- 8.6.5. Entropy
- 8.7. bioMerieux SA
- 8.7.1. Company Overview
- 8.7.2. Company Snapshot
- 8.7.3. Financial Overview
- 8.7.4. Product Listing
- 8.7.5. Entropy
- 8.8. BD
- 8.8.1. Company Overview
- 8.8.2. Company Snapshot
- 8.8.3. Financial Overview
- 8.8.4. Product Listing
- 8.8.5. Entropy
- 8.9. Merck Millipore
- 8.9.1. Company Overview
- 8.9.2. Company Snapshot
- 8.9.3. Financial Overview
- 8.9.4. Product Listing
- 8.9.5. Entropy
- 8.10. Agilent Technologies
- 8.10.1. Company Overview
- 8.10.2. Company Snapshot
- 8.10.3. Financial Overview
- 8.10.4. Product Listing
- 8.10.5. Entropy
- 8.11. Myriad Genetics
- 8.11.1. Company Overview
- 8.11.2. Company Snapshot
- 8.11.3. Financial Overview
- 8.11.4. Product Listing
- 8.11.5. Entropy
- 8.12. Sysmex Corporation
- 8.12.1. Company Overview
- 8.12.2. Company Snapshot
- 8.12.3. Financial Overview
- 8.12.4. Product Listing
- 8.12.5. Entropy
- 8.13. Hologic, Inc.
- 8.13.1. Company Overview
- 8.13.2. Company Snapshot
- 8.13.3. Financial Overview
- 8.13.4. Product Listing
- 8.13.5. Entropy
- 8.14. Quest Diagnostics
- 8.14.1. Company Overview
- 8.14.2. Company Snapshot
- 8.14.3. Financial Overview
- 8.14.4. Product Listing
- 8.14.5. Entropy
- 8.15. Centogene N.V.
- 8.15.1. Company Overview
- 8.15.2. Company Snapshot
- 8.15.3. Financial Overview
- 8.15.4. Product Listing
- 8.15.5. Entropy
- 8.16. PerkinElmer, Inc.
- 8.16.1. Company Overview
- 8.16.2. Company Snapshot
- 8.16.3. Financial Overview
- 8.16.4. Product Listing
- 8.16.5. Entropy
- 8.17. Siemens Healthineers
- 8.17.1. Company Overview
- 8.17.2. Company Snapshot
- 8.17.3. Financial Overview
- 8.17.4. Product Listing
- 8.17.5. Entropy
- 8.18. Exact Sciences
- 8.18.1. Company Overview
- 8.18.2. Company Snapshot
- 8.18.3. Financial Overview
- 8.18.4. Product Listing
- 8.18.5. Entropy
- 8.19. R&D Systems, Inc.
- 8.19.1. Company Overview
- 8.19.2. Company Snapshot
- 8.19.3. Financial Overview
- 8.19.4. Product Listing
- 8.19.5. Entropy
- 8.20. BioVision, Inc.
- 8.20.1. Company Overview
- 8.20.2. Company Snapshot
- 8.20.3. Financial Overview
- 8.20.4. Product Listing
- 8.20.5. Entropy
